• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Stories

‘At the edge of the Congo river’, a one-hour France Culture radio documentary on efforts to eliminate sleeping sickness

Home > Stories

‘At the edge of the Congo river’, a one-hour France Culture radio documentary on efforts to eliminate sleeping sickness

Reporter interviewing patients
6 May 2021

Last Friday evening, listeners of one of France’s most venerable radio stations were treated to an hour-long tribute to the Congolese and international researchers that have dedicated their lives to ending sleeping sickness.

Veteran health reporter Tara Schlegel from France Culture accompanied our NTD Director Dr Nathalie Strub-Wourgaft to the Democratic Republic of Congo (DRC) to witness how the first all-oral treatment for sleeping sickness, fexinidazole, is being rolled out in the country. Her trip, from the capital Kinshasa to a remote rural hospital, was also a trip down Congo’s tumultuous past, where outbreaks of this deadly parasitic disease have ebbed and flowed over time.

Now, as Tara explains, we are finally on the verge of potentially eliminating this disease. The documentary is available in its entirety here.

France Culture is a well-known public radio and news outlet that has built an excellent reputation by broadcasting detailed and well-researched stories on important yet-sometimes overlooked topics. Topics such as neglected diseases. ‘Patients often have no political clout. Affected communities cannot afford treatment and are therefore of little interest to clinical research’, Tara writes in her account of the trip.

Tara landed in Kinshasa on April 11 and started by visiting our DRC regional office, a ‘pretty white house’, with a ‘hand-painted logo’ on the wall, surrounded by ‘blue lizards with red head and tails’, and a ‘large red iron gate; that the driver needs to honk at in order to open’. There she met Dr Wilfried Mutombo Kalonji, our Sleeping Sickness Trial Coordinator, whom she described in colorful terms: ‘a rugby physique, a love of French songs, and a passion for the political history of the Congo and the struggle for independence.’

The DNDi Regional Office in Kinshasa – Photo credit: T.S. – Radio France

Dr Wilfried helped Tara understand the nightmare reputation that sleeping sickness has in his country. Speaking with Tara, he said ‘Some sleep all day. Some have problems with language, behavior, walking. Some also become very aggressive, one spat on my face, another hit the nurse. But I’m not angry: this is because of the disease. They are my friends.‘ If left untreated, patients with sleeping sickness will die.

Dr Wilfried

She also met the legendary Dr Victor Kande: who has devoted his entire career to the fight against sleeping sickness. He described how patients were treated with melarsoprol, the only treatment available to physicians at the time. Derived from arsenic, melarsoprol is so toxic it killed one in 20 patients:  ‘At that time we had up to ten or twenty thousand patients… can you imagine when 5% of them died?’

Tara then accompanied Dr Nathalie, DNDi’s DRC Head of Office Chirac Bulanga Milemba, and Dr Wilfried to Bandundu province, one of the regions most affected by sleeping sickness. The team visited the hospital in Baundundu city,  where DNDi, Sanofi, and various international and Congolese partners carried crucial clinical trials to develop fexinidazole, the simple oral pill that is revolutionizing the treatment of the disease.

Fexinidazole tablet

Near the village of Mushie, Tara met a mobile screening unit – these health workers travel deep into the most remote areas of the DRC to test entire villages for sleeping sickness. ‘This is a very difficult job,’  explained Alexandre Mbukatoto, the unit head. ‘Each month we spend 20 days far from our family and our children, always on the road. Some of us got divorced. The roads are not in good condition, we usually sleep in a villager’s house, or a class room, or a church.‘ But this job is crucial : this screening is necessary to eliminate the last reservoirs of the disease.

Reporter interviewing healthcare worker
Tara Schlegel interviewing Alexandre Mbukatoto

As Dr Nathalie explains in the documentary, ‘the journey from a promising drug candidate to obtaining the authorization to commercialize it took almost ten years.’ And our partnerships are going ever further, as we are developing acoziborole, a new, single-dose, easy to administer pill that holds tremendous promises.

If you speak French – or are learning – please discover more about this fantastic journey by listening to this fabulous audio-documentary.

access the audio-documentary

Photo credit: Nathalie Strub-Wourgaft-DNDi, T.S. – Radio France, Sandrine Francine Ngalula-DNDi

Registration & access Sleeping sickness Democratic Republic of Congo

Read, watch, share

Loading...
Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

Marco Krieger
News
30 Apr 2025

Message on the passing of Dr Marco Aurélio Krieger, Vice-President of Production and Innovation in Health, Fiocruz

Screening activities in village in Guinea
News
25 Apr 2025

Statements from Dr Luis Pizarro and Daisuke Imoto about the Hideyo Noguchi Africa Prize awarded to DNDi

Two man outside of a hospital talking with a nurse
Press releases
24 Apr 2025

Liverpool clinical trial aims to advance life-changing treatment for a deadly parasitic disease

Woman walking in a laboratory
Press releases
23 Apr 2025

DNDi welcomes GHIT support for new project with three Japanese universities to find drug candidates for Chagas disease

Stories
16 Apr 2025

Drug discovery explained: Chagas – How to prove treatments work?

Statements
16 Apr 2025

Statement from the Drugs for Neglected Diseases initiative (DNDi) on the conclusion of WHO Pandemic Agreement negotiations

Press releases
15 Apr 2025

New treatment for cryptococcal meningitis enters Phase II trial as global HIV funding cuts threaten to cause a massive increase in advanced HIV disease

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License